Research Article

A New Platelet-Aggregation-Inhibiting Factor Isolated from *Bothrops moojeni* Snake Venom

Bruna Barbosa de Sousa,^{1,2} Carla Cristine Neves Mamede,^{2,3} Mariana Santos Matias,¹ Déborah Fernanda da Cunha Pereira,¹ Mayara Ribeiro de Queiroz,² Edigar Henrique Vaz Dias,¹ Anielle Christine Almeida Silva,⁴ Noelio Oliveira Dantas,⁴ Júnia de Oliveira Costa,^{1,5} and Fábio de Oliveira^{2,6}

¹Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil

²Instituto Nacional de Ciência e Tecnologia em Nano-Biofarmacêutica (N-Biofar), Belo Horizonte, MG, Brazil

³Instituto de Ciências Agrárias, Universidade Federal de Uberlândia, Monte Carmelo, MG, Brazil

⁴Instituto de Física, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil

⁵Instituto Federal de Educação, Ciência e Tecnologia do Triângulo Mineiro, Campus Ituiutaba, Ituiutaba, MG, Brazil

⁶Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil

Correspondence should be addressed to Júnia de Oliveira Costa; juniacosta@iftm.edu.br and Fábio de Oliveira; foliveira@umuarara.ufu.br

Received 7 July 2017; Revised 12 September 2017; Accepted 24 September 2017; Published 1 November 2017

Academic Editor: Ji-Fu Wei

Copyright © 2017 Bruna Barbosa de Sousa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This work reports the purification and functional characterization of BmooPAi, a platelet-aggregation-inhibiting factor from *Bothrops moojeni* snake venom. The toxin was purified by a combination of three chromatographic steps (ion-exchange on DEAE-Sephacel, molecular exclusion on Sephadex G-75, and affinity chromatography on HiTrap™ Heparin HP). BmooPAi was found to be a single-chain protein with an apparent molecular mass of 32 kDa on 14% SDS-PAGE, under reducing conditions. Sequencing of BmooPAi by Edman degradation revealed the amino acid sequence LGPDIVPPNELLEVM. The toxin was devoid of proteolytic, haemorrhagic, defibrinating, or coagulant activities and induced no significant oedema or hyperalgesia. BmooPAi showed a rather specific inhibitory effect on ristocetin-induced platelet aggregation in human platelet-rich plasma, whereas it had little or no effect on platelet aggregation induced by collagen and adenosine diphosphate. The results presented in this work suggest that BmooPAi is a toxin comprised of disintegrin-like and cysteine-rich domains, originating from autolysis/proteolysis of PIII SVMPs from *B. moojeni* snake venom. This toxin may be of medical interest because it is a platelet aggregation inhibitor, which could potentially be developed as a novel therapeutic agent to prevent and/or treat patients with thrombotic disorders.

1. Introduction

Snake venoms comprise pharmacologically active proteins and peptides, both enzymatic and nonenzymatic, such as phospholipases A₂, metalloproteinases, serine proteinases, nucleotidases, L-amino acid oxidase, disintegrins, and C-type lectins [1–4]. Several snake venom metalloproteinases (SVMPs) have been isolated and characterized by their biological activities. These enzymes play a key role in the prominent local tissue damage and systemic alterations caused by snake venom. SVMPs induce haemorrhage, myonecrosis,

skin damage, inflammation, and degradation of extracellular matrix components. In addition, some SVMPs affect platelet function, while others degrade blood clotting factors, potentiating the haemorrhagic effect [4–8].

SVMPs comprise a group of zinc-dependent enzymes of varying molecular mass, widely distributed in Viperidae venoms. They are synthesized as multidomain precursors and stored in the venom gland as inactive zymogens [7, 9–11]. SVMPs are classified into three major classes, PI, PII, and PIII, according to their size (molecular mass) and domain organization. PI SVMPs include small metalloproteinases with

only the metalloproteinase domain. PII SVMPs comprise medium-size proteinases composed of one metalloproteinase and one disintegrin domain. PIII SVMPs have an additional cysteine-rich domain following the disintegrin-like domain and, in some cases, a lectin-like domain. PII and PIII SVMPs are divided into several subclasses based on proteolytic processing. PII SVMPs can be processed into a metalloproteinase domain and a nonenzymatic disintegrin, and PIII SVMPs can also be degraded, releasing a stable fragment which corresponds to the disintegrin-like and cysteine-rich domains (dis-cys domain) [12, 13].

Several studies have investigated SVMPs as platelet aggregation inhibitors due to their specificity to platelet integrins [4, 7, 10, 14–18]. The disintegrin domain usually contains the RGD (Arg-Gly-Asp) or KGD (Lys-Gly-Asp) motifs in its inhibitory loop, which binds with a high degree of selectivity to the $\alpha_{IIb}\beta_3$ platelet integrin (also known as GPIIb/IIIa), blocking the last phase of platelet aggregation and clot formation [18, 19]. Therefore, SVMPs are considered potent platelet aggregation inhibitors [7]. Unlike the disintegrin domain, whose integrin-binding motif is well characterized, the dis-cys domain possesses the XXCD (X-X-Cys-Asp) motif, instead of the usual RGD, and its targets are not yet fully elucidated. The extant literature indicates that the biological activities attributed to this domain result from its ability to block the interaction of platelets with collagen [19].

In the present study, we describe the isolation and functional characterization of BmooPAi, a toxin comprised of the dis-cys domain, originating from autolysis/proteolysis of PIII SVMPs from *Bothrops moojeni* snake venom, which showed an inhibitory effect on platelet aggregation.

2. Materials and Methods

2.1. Material. Desiccated *B. moojeni* venom was purchased from Bioagents Serpentarium (Batatais, SP, Brazil). Acrylamide, ammonium bicarbonate, ammonium persulphate, azocasein, bromophenol blue, ethylenediaminetetraacetic acid (EDTA), bovine fibrinogen, glycine, β -mercaptoethanol, *N,N'*-methylene-bis-acrylamide, sodium dodecyl sulphate (SDS), *N,N,N',N'*-tetramethylethylenediamine (TEMED), and Tris were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Molecular weight markers for electrophoresis and all chromatographic media (DEAE-Sephacel, Sephadex G-75, HiTrap Heparin HP and C2/C18 columns) were purchased from GE Healthcare Technologies (Uppsala, Sweden). All the agonists used in the platelet aggregation assays (collagen from equine tendon, adenosine diphosphate (ADP), and ristocetin) were purchased from Helena Laboratories (Beaumont, Texas, USA). All other reagents used were of analytical grade.

2.2. Animals. Male Swiss mice (20–25 g) and male Wistar rats (200–250 g) were provided by the Centro de Bioterismo e Experimentação Animal (CEBEA) at the Federal University of Uberlândia (Uberlândia-MG, Brazil). The animals were maintained under conditions of controlled temperature ($22 \pm 2^\circ\text{C}$) and light/dark cycle (12 hours) with free access to food and water. The experimental protocol was approved by the Committee for Ethics in Animal Experimentation of

the Federal University of Uberlândia (CEUA/UFU), Minas Gerais, Brazil (Protocol number 108/12).

2.3. Human Blood. The experiments were performed in accordance with current guidelines for human research, established by the Committee for Ethics in Human Research of the Federal University of Uberlândia, Minas Gerais, Brazil (CEP/UFU, Protocol number 1.627.982/2016). Blood was obtained by blood donation from 10 individuals who were invited to participate in the research as volunteer donors. The criteria for the selection of donor volunteers included no signs or symptoms of disease, malnutrition, or dehydration; age between 18 and 65 years; weight more than 50 kg; no use of any medication that interferes with haemostasis; no use of illicit drugs; no alcohol consumption in the last 24 hours preceding the experiment; and no haemostasis disorders.

2.4. Isolation of BmooPAi. Protein isolation was carried out in three steps. The crude venom of *B. moojeni* (200 mg) was dissolved in 2.0 mL of 0.05 M ammonium bicarbonate buffer (pH 7.8) and clarified by centrifugation at $10,000 \times g$ for 10 min. The supernatant was applied to a DEAE-Sephacel column (2.5×20 cm) previously equilibrated with 0.05 M ammonium bicarbonate buffer (pH 7.8). Chromatography was carried out at a flow rate of 20 mL/h, with a linear concentration gradient of the same buffer (0.05–0.6 M), and fractions of 3.0 mL/tube were collected. All peaks were monitored by measuring absorbance at 280 nm on a spectrophotometer (BioSpec-Mini; Shimadzu Biotech, Japan). The seventh peak, designated D7, was pooled, lyophilised, and applied to a Sephadex G-75 column (1.0×100 cm) previously equilibrated with 0.05 M ammonium bicarbonate buffer (pH 7.8). The samples were eluted from this column with the same buffer, at a flow rate of 20 mL/h, and fractions of 3.0 mL/tube were collected. The second fraction, designated D7S2, was pooled, lyophilised, and submitted to the third step of separation using a HiTrap Heparin HP column (5×1 mL) in an ÄKTApurifier™ HPLC system, previously equilibrated with 20 mM Tris-HCl buffer (pH 7.0) containing 5 mM calcium chloride. The samples were eluted with an increasing concentration gradient of 20 mM Tris-HCl buffer (pH 7.0) containing 2.0 M sodium chloride. Elution was carried out at a flow rate of 30 mL/h; fractions of 1.0 mL/tube were collected and the absorbance was read at 280 nm. Isolated BmooPAi was concentrated in the major peak. To evaluate the degree of purity, isolated BmooPAi was passed through a reverse-phase C2/C18 column (4.6×100 mm) using the ÄKTApurifier HPLC system. The column was equilibrated with solvent A (0.1% trifluoroacetic acid) and eluted with a linear concentration gradient from 0 to 100% of solvent B (70% acetonitrile, 0.1% trifluoroacetic acid) at a flow rate of 0.3 mL/min. Absorbance was monitored at 280 nm.

2.5. Protein Analysis. The protein concentration was determined using the method established by Bradford [20]. Determination of the protein concentration was performed in triplicate and the absorbance was measured at 595 nm. The protein concentration (mg/ μL) was determined from linear regression calculations based on the values obtained from

the standard curve. Polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulphate (SDS-PAGE) was performed using 14% (w/v) gels. Electrophoresis was carried out at 20 mA/gel in Tris-glycine buffer (pH 8.3) containing 0.01% SDS. The molecular mass standard proteins used included phosphorylase b (97 kDa), bovine serum albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), soybean trypsin inhibitor (20.1 kDa), and α -lactalbumin (14.4 kDa). Gels were stained with Coomassie blue R-250, 0.2% (w/v). The relative molecular mass of BmooPAi was estimated using Kodak 1D image analysis software.

2.6. N-Terminal Sequencing. The sequencing was performed in a membrane obtained from the purified protein in solution. The liquid sample was loaded onto an Applied Biosystems Prosorb™ device. The protocol for sample preparation using this device was followed, and the Prosorb membrane was loaded onto the instrument for sequence analysis.

2.7. Proteolytic Activity upon Fibrinogen. Fibrinogenolytic activity was assayed as previously described [21], with brief modifications. Samples containing 25 μ L of bovine fibrinogen (3 mg/mL saline) were incubated with 20 μ g of BmooPAi for 120 min at 37°C. The reaction was stopped by the addition of a denaturing buffer containing 10% (v/v) glycerol, 10% (v/v) β -mercaptoethanol, 0.2% (w/v) SDS, and 0.001% (w/v) bromophenol blue (pH 6.8). Reaction products were analysed using 14% (w/v) SDS-PAGE.

2.8. Proteolytic Activity upon Azocasein. Samples of 20 μ g BmooPAi were supplemented with 200 μ L of saline and incubated for 60 min with 800 μ L of azocasein solution (1 mg/mL). The reaction was stopped by the addition of 200 μ L of 15% trichloroacetic acid to precipitate the undegraded azocasein. The mixture was left standing for 20 min before centrifugation at 10,000 $\times$ g for 10 min. The proteolytic activity was estimated by reading the absorbance of the clear supernatant at 405 nm. One unit of azocaseinolytic activity was defined as the amount of enzyme that produced an absorbance increase of 0.01 units.

2.9. Haemorrhagic Activity. Haemorrhagic activity was determined as previously described [22], with some modifications. Groups of three male Swiss mice were administered a dorsal skin subcutaneous injection of 50 μ g BmooPAi diluted in 25 μ L of saline. After three hours, animals were euthanized by an overdose of ketamine/xylazine, the skin was removed and the diameter of the haemorrhagic spot was measured on the inner surface. Control animals received the same volume of sterile saline.

2.10. Defibrinating Activity. Defibrinating activity was carried out as previously described [23], with slight modifications. Groups of three male Swiss mice were intraperitoneally injected with 50 μ g BmooPAi (50 μ g/100 μ L saline). Control animals received the same volume of sterile saline. After one hour, mice were euthanized by an overdose of ketamine/xylazine and bled by cardiac puncture. Whole blood was placed in tubes and kept at 25–30°C. Activity was

determined by measuring the time to the onset of blood clotting.

2.11. Coagulant Activity. Coagulant activity was assayed using bovine plasma. The plasma samples were mixed with 3.8% sodium citrate (9:1, v/v) and centrifuged at 2,500 $\times$ g for 15 min to obtain platelet-rich plasma (PRP). BmooPAi (25 μ g/25 μ L), the same volume of saline (negative control), or 0.2 mol/L calcium chloride (positive control) was added to 200 μ L of citrated bovine PRP at 37°C. Clotting activity was determined by measuring the time to fibrin clot onset by a coagulometer (CLO Timer).

2.12. Evaluation of Paw Oedema Formation. Groups of three male Wistar rats received an intraplantar injection of BmooPAi (50 μ g/100 μ L saline) into the subplantar region of one hind paw. An equal volume of sterile saline was injected into the contralateral paw. The volume of each paw was measured using a plethysmometer (model 7140; Ugo Basile, Italy) before and 1, 2, 3, 4, 5, 6, and 24 h after the injection. Results were calculated as the difference between each paw and expressed as the percentage increase in paw volume relative to the initial volume.

2.13. Evaluation of Hyperalgesia. Hyperalgesia was measured according to the paw pressure test, as previously described [24], with slight modifications. Groups of three male Wistar rats received an intraplantar injection of BmooPAi (50 μ g/100 μ L saline) into the right hind paw. An equal volume of sterile saline was injected into the left hind paw for control. The weight in grams (g) required to elicit a nociceptive response, that is, paw flexion, was determined as the nociceptive threshold. A cut-off value of 300 g was used to prevent damage to the paws. The nociceptive threshold was measured before and 1, 2, 3, 4, 5, 6, and 24 h after BmooPAi injection using a Randall-Selitto apparatus (EFF-440 model; Insight, Brazil). Results were calculated as the difference between each paw and expressed as the percentage decrease in nociceptive threshold relative to the initial threshold. To reduce stress, the rats were habituated to the apparatus one day before the experiment.

2.14. Platelet Aggregation Assay. Platelet aggregation assays were performed as previously described [25] in human PRP and measured using the automatic Aggregometer 4 channels (AggRAM™ version 1.1; Helena Laboratories, USA). Human blood collected in sodium citrate was centrifuged at 100 $\times$ g for 12 min at room temperature to obtain PRP. Platelet-poor plasma (PPP) was obtained from the residue by centrifugation of citrated blood at 1,000 $\times$ g for 15 min. Assays were carried out using 200 μ L of PRP maintained at 37°C under continuous stirring, in siliconized glass cuvettes. Aggregation was triggered with collagen (10 μ g/mL), ADP (20 μ M), or ristocetin (1.5 mg/mL) immediately after adding BmooPAi (10, 25 and 50 μ g) to human PRP. Finally, 100% aggregation was expressed as the percentage absorbance relative to PPP aggregation. Control experiments were performed using only platelet agonists. All experiments were carried out in triplicate.

3. Results and Discussion

In recent years, a number of snake venom proteins that interfere with platelet function have been identified. Most of these proteins belong to the SVMP family, and their effects are probably due to the presence of dis-cys domains which interact with specific protein molecules on platelet membrane surfaces [25–29]. In this work, we report the purification and functional characterization of BmooPAi, a platelet-aggregation-inhibiting factor, comprised of dis-cys domains processed from PIII SVMPs from *B. moojeni* snake venom.

The toxin was isolated using a three-step procedure, including ion-exchange, gel filtration, and affinity chromatographies. Other toxins have been purified using similar procedures, including BmooFIBMP-I [30] and BmooMP α -1 [31], both metalloproteinases purified from *B. moojeni* snake venom. *B. moojeni* crude venom (200 mg) was applied to ion-exchange chromatography on a DEAE-Sephacel column, which produced eight main protein peaks, designated D1 to D8 (Figure 1(a)). The D7 fraction represented around 5.5% (w/w) of the crude venom; it was submitted to gel filtration chromatography on a Sephadex G-75 column, resulting in four peaks, designated D7S1 to D7S4 (Figure 1(b)). The D7S2 fraction (~3.3%) was further fractionated over an affinity chromatography HiTrap Heparin HP column using the ÄKTApurifier HPLC system (Figure 1(c)). The nonadsorbed fraction (~1.7%) was able to inhibit platelet aggregation and it was designated BmooPAi (platelet aggregation inhibitor from *B. moojeni*). This fraction was devoid of proteolytic, haemorrhagic, defibrinating, or coagulant activities. In addition, BmooPAi did not cause hyperalgesia and oedematogenic responses in the hind paw when rats received a 50 μ g intraplantar injection of the toxin. Thus, BmooPAi does not contribute to the local effects caused by *B. moojeni* envenomation.

The homogeneity of this sample was demonstrated by SDS-PAGE, showing a single protein band around 32 kDa in the presence or absence of the reducing agent β -mercaptoethanol (Figure 1(d)). The degree of purity of the isolated BmooPAi was confirmed by reverse-phase HPLC chromatography on a C2/C18 column, revealing a unique major peak (Figure 1(e)).

BmooPAi was subjected to N-terminal sequencing by Edman degradation. The first 15 amino acid residues from N-terminal sequencing were determined to be LGPDIVPP-NELLEVM and were submitted to BLAST. The primary sequence of BmooPAi shared similarity with the middle of some PIII SVMPs, skipping the catalytic domain, and with some disintegrin or disintegrin-like proteins. Moojenin (GI: P0DKR0.1), Bothropasin (GI: 209870468), Jararhagin (GI: P30431.1), Leucurolysin-B (GI: P86092.1), Brevilysin-H6 (GI: P0C7B0.2), Atrolysin-A (GI: Q92043.1), and AaH-IV (GI: 255917952) are PIII SVMPs that showed homology with BmooPAi; Jarastatin (GI: Q0NZX5.1), Jararhagin-C (GI: P30431.1), Leucurogin (GI: P0DJ87.1), and Salmosin (GI: O93518.1) are disintegrin or disintegrin-like proteins homologous to BmooPAi (Figure 2).

PIII SVMPs comprise high molecular mass proteinases composed of a dis-cys domain following the proteinase

domain. Some PIII SVMPs have an additional lectin-like domain linked to the others through a disulphide bond [12, 13]. SVMPs play an important role in haemostatic disorders. They are the primary factors responsible for haemorrhage [32]. PIII SVMPs are more able to induce haemorrhage than PI and PII classes due to the presence of the additional dis-cys domain which contributes to the proteolytic specificity of these enzymes, directing them to bind to critical components of the microvasculature [28, 33]. Subclass PIIIb SVMPs can undergo proteolysis/autolysis during secretion or under nonphysiological conditions *in vitro*, such as alkaline pH, low calcium, or the presence of reducing agents, generating intact biologically active polypeptides of ~30 kDa, which correspond to the dis-cys domain [13, 34].

Although BmooPAi showed high homology with many PIII SVMPs, it showed no haemorrhagic activity. These data suggest that this toxin originated from the proteolysis/autolysis of a PIII SVMP and comprises only the noncatalytic dis-cys domain. For this reason, BmooPAi was not able to induce haemorrhage due to the absence of the proteinase domain, preventing proteolysis of the capillary components.

Some PIII SVMPs homologous to BmooPAi, such as Bothropasin [35], Brevilysin-H6 [36], Leucurolysin-B [37], AaH-IV [38], and Jararhagin [39], can be cleaved through autoproteolytic events, releasing the dis-cys domain. According to the characteristics of BmooPAi, we suggest that this toxin is similar to Jararhagin-C (28 kDa) [40] and Acucetin (30 kDa) [41]. Both toxins are composed of the dis-cys domain with a molecular mass of approximately 30 kDa released through autoproteolysis of Jararhagin from *B. jararaca* [39] and AaH-IV from *Agkistrodon acutus* [38]. Similar to BmooPAi, Jararhagin-C and Acucetin do not induce haemorrhage. For this reason, we suggest that BmooPAi originates from the class of PIII SVMPs, as proposed by Fox and Serrano [13], in which the dis-cys domain has been processed from the proteinase domain.

The extant literature shows that several PIII SVMPs and processed dis-cys domains are able to interfere with platelet aggregation, including Jararhagin [39], Jararhagin-C [40], Alternagin-C [42], Leucurogin [43], and Leberagin-C [44]. Their targets on platelet membranes include the receptors GPIIb-IX-V, $\alpha_{IIb}\beta_3$ integrin (GPIIb-IIIa), $\alpha_2\beta_1$ integrin, and GPVI and also their ligands, von Willebrand factor (vWF), fibrinogen, and/or collagen [4, 45]. In this work, BmooPAi was tested for its effect on platelet aggregation. Figure 3(a) shows that BmooPAi inhibited platelet aggregation induced by ristocetin in a dose-dependent manner, although it had little or no effect on platelet aggregation induced by ADP (Figure 3(b)) and collagen (Figure 3(c)). Our results showed that 10 and 25 μ g of BmooPAi inhibited approximately 32% and 72% of ristocetin-induced platelet aggregation, respectively, whereas 50 μ g completely inhibited platelet aggregation induced by ristocetin. On the other hand, BmooPAi was not able to inhibit the platelet aggregation induced by ADP and collagen, even at high concentrations (50 μ g).

According to Collier and Gralnick [46], ristocetin is an antibiotic that induces vWF-GPIIb binding *in vitro*, even at static conditions. This interaction plays a key role in the initial adhesion of platelets to the subendothelium, which

FIGURE 1: Purification of BmoopAi from *B. moojeni* snake venom. (a) Separation on DEAE-Sephacel ion-exchange chromatography: crude venom (200 mg) was applied to the column (2.5 × 20 cm) and elution was carried out at a flow rate of 20 mL/h with ammonium bicarbonate (Ambic) buffer gradients, pH 7.8, from 0.05 M to 0.6 M. Fractions of 3.0 mL/tube were collected and the absorbance was read at 280 nm. (b) Separation on Sephadex G-75 molecular exclusion chromatography: fraction D7 was applied to the column (1.0 × 100 cm) and elution with 0.05 M ammonium bicarbonate was achieved at a flow rate of 20 mL/h. Fractions of 3.0 mL/tube were collected and the absorbance was read at 280 nm. (c) Separation by affinity chromatography on a HiTrap Heparin HP column using the ÄKTApurifier HPLC system: fraction D7S2 was applied to the column (5 × 1 mL), previously equilibrated with 20 mM Tris-HCl buffer (pH 7.0) containing 5 mM calcium chloride. The samples were eluted with an increasing concentration gradient of 20 mM Tris-HCl buffer (pH 7.0) containing 2.0 M sodium chloride, and the absorbance of the fractions was monitored at 280 nm. Fractions of 1.0 mL/tube were collected at a flow rate of 30 mL/h. (d) SDS-PAGE in 14% (w/v) polyacrylamide, Tris-glycine buffer, pH 8.3, and 20 mA. Lanes: 1, standard proteins; 2, reduced crude venom of *B. moojeni*; 3, reduced BmoopAi; 4, nonreduced BmoopAi. The gel was stained with Coomassie blue R-250. (e) Reverse-phase HPLC on a C2C18 column (4.6 × 100 mm) equilibrated with 0.1% trifluoroacetic acid (TFA) and eluted with a linear concentration gradient from 0 to 100% of solution B (70% acetonitrile in 0.1% TFA).

FIGURE 2: Sequence alignment of BmooPAi and other metalloproteinases/dis-cys proteins: Moojenin (GI: P0DKR0.1), Bothropasin (GI: 209870468), Jararhagin (GI: P30431.1), Jarastatin (GI: Q0NZX5.1), Jararhagin-C (GI: P30431.1), Leucurolysin-B (GI: P86092.1), Leucurogin (GI: P0DJ87.1), Brevilysin-H6 (GI: P0C7B0.2), AaH-IV (GI: 255917952), Atrolysin-A (GI: Q92043.1), and Salmosin (GI: O93518.1). The nonconserved residues are shown in black frames. The alignment and figure were generated by the MegAlign program from Lasergene (DNASTar Inc., Madison, WI, USA).

in turn induces a complex cascade of signals which results in platelet aggregation [47]. Since the circulating native form of vWF does not bind to platelet GPIb under static conditions, the antibiotic ristocetin allows the reproduction of the platelet aggregation events *in vitro* [48]. The importance of vWF-GPIb binding has been demonstrated for the clinical subsidiary diagnosis of hemostatic disorders, such as Bernard-Soulier syndrome [49] and von Willebrand disease [50].

A number of haemostatically active proteins that inhibit ristocetin (or botrocetin, a snake venom protein that also promotes *in vitro* vWF-GPIb binding)-induced platelet aggregation have been isolated and characterized from the venom of several snake species [3, 15]. Echicetin [51], Agkicetin [52], Jararaca GPIb-BP [53], Tokaracetin [54], Crotalin [55], Jararhagin [56], Kaouthiagin [57], Acurhagin [58], Kistomin [59], and Mocarhagin [60] are some examples.

Echicetin, Agkicetin, Jararaca GPIb-BP, and Tokaracetin toxins belong to the C-type lectin family and are able to bind directly to GPIb, blocking the binding of vWF to GPIb [61]. Jararhagin, Kaouthiagin, Acurhagin, Kistomin, Mocarhagin, and Crotalin belong to the SVMP family and are able to

inhibit ristocetin-induced platelet aggregation due to their catalytic effect on GPIb and/or vWF [15]. BmooPAi also interferes with the vWF-GPIb interaction, but since it has no catalytic effect, we suggest that BmooPAi acts as an antagonist of the GPIb receptor, as described in other works. It is probable that the presence of the dis-cys domain directs the toxin to the platelet receptor. Furthermore, as BmooPAi did not inhibit ADP- or collagen-induced platelet aggregation, we can rule out the possibility of activity toward $\alpha_2\beta_1$, GPVI, P2Y1, and P2Y12 receptors. The initial findings from this work in progress provide impetus to further investigate the mechanism of action of BmooPAi on the platelet receptor.

4. Conclusions

In conclusion, we describe the procedures for isolation of BmooPAi (32 kDa), a toxin comprised of the dis-cys domain, originating from autolysis/proteolysis of PIII SVMPs from *B. moojeni* venom. BmooPAi may be of medical interest because it is a platelet aggregation inhibitor that interferes with the vWF-GPIb interaction. This toxin can be used to better understand the mechanisms concerning haemostasis

FIGURE 3: Effect of BmoopAi from *B. moojeni* venom on (a) ristocetin-, (b) ADP-, and (c) collagen-induced platelet aggregation. Aggregation was triggered with the agonists immediately after adding the indicated doses of BmoopAi to citrated human PRP at 37°C. Platelet aggregation was recorded for 10 min in an AggRAM platelet aggregation system with four-channel laser optics (Helena Laboratories, EUA). Results are expressed as an increase in light transmission, where PPP represents the maximum response (100%). Control experiments were performed in the absence of BmoopAi.

and could potentially be used as a tool for the development of novel antithrombotic agents.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Ministério de Ciências e Tecnologia (MCT) of Brazil.

References

- [1] X.-Y. Du, D. S. Sim, W.-H. Lee, and Y. Zhang, "Blood cells as targets of snake toxins," *Blood Cells, Molecules, and Diseases*, vol. 36, no. 3, pp. 414–421, 2006.
- [2] R. M. Kini and H. J. Evans, "Effects of snake venom proteins on blood platelets," *Toxicon*, vol. 28, no. 12, pp. 1387–1422, 1990.
- [3] F. S. Markland, "Snake venoms and the hemostatic system," *Toxicon*, vol. 36, no. 12, pp. 1749–1800, 1998.
- [4] T. Sajevec, A. Leonardi, and I. Križaj, "Haemostatically active proteins in snake venoms," *Toxicon*, vol. 57, no. 5, pp. 627–645, 2011.
- [5] J. W. Fox and S. M. T. Serrano, "Timeline of key events in snake venom metalloproteinase research," *Journal of Proteomics*, vol. 72, no. 2, pp. 200–209, 2009.
- [6] J. M. Gutiérrez and A. Rucavado, "Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage," *Biochimie*, vol. 82, no. 9–10, pp. 841–850, 2000.
- [7] F. S. Markland and S. Swenson, "Snake venom metalloproteinases," *Toxicon*, vol. 62, pp. 3–18, 2013.
- [8] N. Marsh and V. Williams, "Practical applications of snake venom toxins in haemostasis," *Toxicon*, vol. 45, no. 8, pp. 1171–1181, 2005.
- [9] J. J. Calvete, P. Juárez, and L. Sanz, "Snake venomomics. Strategy and applications," *Journal of Mass Spectrometry*, vol. 42, no. 11, pp. 1405–1414, 2007.
- [10] A. M. Moura-da-Silva, D. Butera, and I. Tanjoni, "Importance of snake venom metalloproteinases in cell biology: Effects on platelets, inflammatory and endothelial cells," *Current Pharmaceutical Design*, vol. 13, no. 28, pp. 2893–2905, 2007.
- [11] S. Swenson and F. S. Markland Jr., "Snake venom fibrin(ogen)olytic enzymes," *Toxicon*, vol. 45, no. 8, pp. 1021–1039, 2005.
- [12] J. W. Fox and S. M. T. Serrano, "Structural considerations of the snake venom metalloproteinases, key members of the M12 reprotolysin family of metalloproteinases," *Toxicon*, vol. 45, no. 8, pp. 969–985, 2005.
- [13] J. W. Fox and S. M. T. Serrano, "Insights into and speculations about snake venom metalloproteinase (SVMP) synthesis, folding and disulfide bond formation and their contribution to venom complexity," *FEBS Journal*, vol. 275, no. 12, pp. 3016–3030, 2008.
- [14] S. Braud, C. Bon, and A. Wisner, "Snake venom proteins acting on hemostasis," *Biochimie*, vol. 82, no. 9–10, pp. 851–859, 2000.
- [15] A. S. Kamiguti, "Platelets as targets of snake venom metalloproteinases," *Toxicon*, vol. 45, no. 8, pp. 1041–1049, 2005.

- [16] C. Y. Koh and R. M. Kini, "From snake venom toxins to therapeutics—cardiovascular examples," *Toxicon*, vol. 59, no. 4, pp. 497–506, 2012.
- [17] T. Matsui, Y. Fujimura, and K. Titani, "Snake venom proteases affecting hemostasis and thrombosis," *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology*, vol. 1477, no. 1-2, pp. 146–156, 2000.
- [18] O. H. P. Ramos and H. S. Selistre-De-Araujo, "Snake venom metalloproteases - Structure and function of catalytic and disintegrin domains," *Comp Biochem Physiol C Toxicol Pharmacol*, vol. 142, no. 3-4, pp. 328–346, 2006.
- [19] J. J. Calvete, C. Marcinkiewicz, D. Monleón et al., "Snake venom disintegrins: Evolution of structure and function," *Toxicon*, vol. 45, no. 8, pp. 1063–1074, 2005.
- [20] M. M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding," *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.
- [21] V. M. Rodrigues, A. M. Soares, R. Guerra-Sá, V. Rodrigues, M. R. M. Fontes, and J. R. Giglio, "Structural and functional characterization of neuwiedase, a nonhemorrhagic fibrin(ogen)olytic metalloprotease from Bothrops neuwiedi snake venom," *Archives of Biochemistry and Biophysics*, vol. 381, no. 2, pp. 213–224, 2000.
- [22] T. Nikai, N. Mori, M. Kishida, H. Sugihara, and A. T. Tu, "Isolation and biochemical characterization of hemorrhagic toxin f from the venom of Crotalus atrox (Western Diamondback Rattlesnake)," *Archives of Biochemistry and Biophysics*, vol. 231, no. 2, pp. 309–319, 1984.
- [23] J. Gené, A. Roy, G. Rojas, J. Gutiérrez, and L. Cerdas, "Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom," *Toxicon*, vol. 27, no. 8, pp. 841–848, 1989.
- [24] L. O. Randall and J. J. Selitto, "A method for measurement of analgesic activity on inflamed tissue," *Archives Internationales de Pharmacodynamie et de Thérapie*, vol. 111, no. 4, pp. 409–419, 1957.
- [25] M. R. De Queiroz, C. C. N. Mamede, K. C. Fonseca et al., "Rapid purification of a new P-I class metalloproteinase from Bothrops moojeni venom with antiplatelet activity," *BioMed Research International*, vol. 2014, Article ID 352420, 2014.
- [26] R. K. Andrews and M. C. Berndt, "Snake venom modulators of platelet adhesion receptors and their ligands," *Toxicon*, vol. 38, no. 6, pp. 775–791, 2000.
- [27] M. R. de Queiroz, B. B. de Sousa, D. F. da Cunha Pereira et al., "The role of platelets in hemostasis and the effects of snake venom toxins on platelet function," *Toxicon*, vol. 133, pp. 33–47, 2017.
- [28] S. M. T. Serrano, J. Kim, D. Wang et al., "The cysteine-rich domain of snake venom metalloproteinases is a ligand for von Willebrand factor A domains: Role in substrate targeting," *The Journal of Biological Chemistry*, vol. 281, no. 52, pp. 39746–39756, 2006.
- [29] S. M. T. Serrano, D. Wang, J. D. Shannon, A. F. M. Pinto, R. K. Polanowska-Grabowska, and J. W. Fox, "Interaction of the cysteine-rich domain of snake venom metalloproteinases with the A1 domain of von Willebrand factor promotes site-specific proteolysis of von Willebrand factor and inhibition of von Willebrand factor-mediated platelet aggregation," *FEBS Journal*, vol. 274, no. 14, pp. 3611–3621, 2007.
- [30] F. S. Torres, B. Rates, M. T. Gomes et al., "Bmoo FIBMP-I: A New Fibrinogenolytic Metalloproteinase from," *ISRN Toxicology*, vol. 2012, pp. 1–10, 2012.
- [31] C. P. Bernardes, N. A. Santos-Filho, T. R. Costa et al., "Isolation and structural characterization of a new fibrin(ogen)olytic metalloproteinase from Bothrops moojeni snake venom," *Toxicon*, vol. 51, no. 4, pp. 574–584, 2008.
- [32] T. Escalante, A. Rucavado, J. W. Fox, and J. M. Gutiérrez, "Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases," *Journal of Proteomics*, vol. 74, no. 9, pp. 1781–1794, 2011.
- [33] L.-G. Jia, X.-M. Wang, J. D. Shannon, J. B. Bjarnason, and J. W. Fox, "Function of disintegrin-like/cysteine-rich domains of atrolysin A. Inhibition of platelet aggregation by recombinant protein and peptide antagonists," *The Journal of Biological Chemistry*, vol. 272, no. 20, pp. 13094–13102, 1997.
- [34] M. T. Assakura, C. A. Silva, R. Mentele, A. C. M. Camargo, and S. M. T. Serrano, "Molecular cloning and expression of structural domains of bothropasin, a P-III metalloproteinase from the venom of Bothrops jararaca," *Toxicon*, vol. 41, no. 2, pp. 217–227, 2003.
- [35] F. R. Mandelbaum, A. P. Reichel, and M. T. Assakura, "Isolation and characterization of a proteolytic enzyme from the venom of the snake Bothrops jararaca (Jararaca)," *Toxicon*, vol. 20, no. 6, pp. 955–972, 1982.
- [36] S. Fujimura, K. Oshikawa, S. Terada, and E. Kimoto, "Primary structure and autoproteolysis of brevilysin H6 from the venom of Gloydus halys brevicaudus," *The Journal of Biochemistry*, vol. 128, no. 2, pp. 167–173, 2000.
- [37] E. F. Sanchez, L. M. Gabriel, S. Gontijo et al., "Structural and functional characterization of a P-III metalloproteinase, leucurolysin -B, from Bothrops leucurus venom," *Archives of Biochemistry and Biophysics*, vol. 468, no. 2, pp. 193–204, 2007.
- [38] Z. Zhu, W. Gong, X. Zhu, M. Teng, and L. Niu, "Purification, characterization and conformational analysis of a hemorrhagin from the venom of Agkistrodon acutus," *Toxicon*, vol. 35, no. 2, pp. 283–292, 1997.
- [39] M. J. I. Paine, H. P. Desmond, R. D. G. Theakston, and J. M. Crampton, "Purification, cloning, and molecular characterization of a high molecular weight hemorrhagic metalloprotease, jararhagin, from Bothrops jararaca venom. Insights into the disintegrin gene family," *The Journal of Biological Chemistry*, vol. 267, no. 32, pp. 22869–22876, 1992.
- [40] Y. Usami, Y. Fujimura, S. Miura et al., "A 28-kDa Protein with Disintegrin-like Structure (Jararhagin-C) Purified from Bothrops jararaca Venom Inhibits Collagen- and ADP-Induced Platelet Aggregation," *Biochemical and Biophysical Research Communications*, vol. 201, no. 1, pp. 331–339, 1994.
- [41] J. Zang, Z. Zhu, Y. Yu et al., "Purification, partial characterization and crystallization of acucetin, a protein containing both disintegrin-like and cysteine-rich domains released by autoproteolysis of a P-III-type metalloproteinase AaH-IV from Agkistrodon acutus venom," *Acta Crystallographica - Section D Biological Crystallography*, vol. 59, no. 12, pp. 2310–2312, 2003.
- [42] H. S. Selistre-de-Araujo, M. R. Cominetti, C. H. B. Terruggi et al., "Alternagin-C, a disintegrin-like protein from the venom of Bothrops alternatus, modulates $\alpha 2 \beta 1$ integrin-mediated cell adhesion, migration and proliferation," *Brazilian Journal of Medical and Biological Research*, vol. 38, no. 10, pp. 1505–1511, 2005.
- [43] D. A. Higuchi, M. C. Almeida, C. C. Barros et al., "Leucurogin, a new recombinant disintegrin cloned from Bothrops leucurus

- (white-tailed-jararaca) with potent activity upon platelet aggregation and tumor growth," *Toxicon*, vol. 58, no. 1, pp. 123–129, 2011.
- [44] I. Limam, A. Bazaa, N. Srairi-Abid et al., "Leberagin-C, A disintegrin-like/cysteine-rich protein from *Macrovipera lebetina* transmediterranea venom, inhibits alphavbeta3 integrin-mediated cell adhesion," *Matrix Biology*, vol. 29, no. 2, pp. 117–126, 2010.
- [45] R. K. Andrews, A. S. Kamiguti, O. Berlanga, M. Leduc, R. D. G. Theakston, and S. P. Watson, "The use of snake venom toxins as tools to study platelet receptors for collagen and von Willebrand factor," *Pathophysiology of Haemostasis and Thrombosis*, vol. 31, no. 3-6, pp. 155–172, 2001.
- [46] B. S. Collier and H. R. Gralnick, "Studies on the mechanism of ristocetin induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin," *The Journal of Clinical Investigation*, vol. 60, no. 2, pp. 302–312, 1977.
- [47] K. Jurk and B. E. Kehrel, "Platelets: Physiology and biochemistry," *Seminars in Thrombosis and Hemostasis*, vol. 31, no. 4, pp. 381–392, 2005.
- [48] A. Navdaev, H. Subramanian, A. Petunin, K. J. Clemetson, S. Gambaryan, and U. Walter, "Echicetin coated polystyrene beads: A novel tool to investigate GPIIb-specific platelet activation and aggregation," *PLoS ONE*, vol. 9, no. 4, Article ID e93569, 2014.
- [49] A. T. Nurden, D. Didry, and J. P. Rosa, "Molecular defects of platelets in Bernard-Soulier syndrome," *Blood Cells*, vol. 9, no. 2, pp. 333–358, 1983.
- [50] Z. M. Ruggeri, "Developing basic and clinical research on von Willebrand factor and von Willebrand disease," *Thrombosis and Haemostasis*, vol. 84, no. 2, pp. 147–149, 2000.
- [51] M. Peng, W. Lu, L. Beviglia, S. Niewiarowski, and E. P. Kirby, "Echicetin: A snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib," *Blood*, vol. 81, no. 9, pp. 2321–2328, 1993.
- [52] Y. L. Chen and I. H. Tsai, "Functional and Sequence Characterization of Agkicetin, a New Glycoprotein IB Antagonist Isolated from *Agkistrodon acutus* Venom," *Biochemical and Biophysical Research Communications*, vol. 210, no. 2, pp. 472–477, 1995.
- [53] Y. Fujimura, Y. Ikeda, S. Miura et al., "Isolation and characterization of jararaca GPIIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib," *Thrombosis and Haemostasis*, vol. 74, no. 2, pp. 743–750, 1995.
- [54] T. Kawasaki, Y. Taniuchi, N. Hisanichi et al., "Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein Ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation," *Biochemical Journal*, vol. 308, no. 3, pp. 947–953, 1995.
- [55] B. S. Collier, "Anti-GPIIb-IIIa drugs: current strategies and future directions," *Thrombosis and Haemostasis*, vol. 86, no. 1, pp. 427–443, 2001.
- [56] A. S. Kamiguti, C. R. M. Hay, R. D. G. Theakston, and M. Zuzel, "Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases," *Toxicon*, vol. 34, no. 6, pp. 627–642, 1996.
- [57] J. Hamako, T. Matsui, S. Nishida et al., "Purification and characterization of kaouthiagin, a von Willebrand factor-binding and -cleaving metalloproteinase from *Naja kaouthia* cobra venom," *Thrombosis and Haemostasis*, vol. 80, no. 3, pp. 499–505, 1998.
- [58] W.-J. Wang and T.-F. Huang, "Purification and characterization of a novel metalloproteinase, acurhagin, from *Agkistrodon acutus* venom," *Thrombosis and Haemostasis*, vol. 87, no. 4, pp. 641–650, 2002.
- [59] T.-F. Huang, M.-C. Chang, and C.-M. Teng, "Antiplatelet protease, kistomin, selectively cleaves human platelet glycoprotein Ib," *BBA - General Subjects*, vol. 1158, no. 3, pp. 293–299, 1993.
- [60] C. M. Ward, R. K. Andrews, A. I. Smith, and M. C. Berndt, "Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ib α . Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ib α as a binding site for von Willebrand factor and α -thrombin," *Biochemistry*, vol. 35, no. 15, pp. 4929–4938, 1996.
- [61] G. Xu, H. Ulrichs, S. Vauterin et al., "How does agkicetin-C bind on platelet glycoprotein Ib α and achieve its platelet effects?" *Toxicon*, vol. 45, no. 5, pp. 561–570, 2005.